List of Harvoni drug patents

Harvoni is owned by Gilead Sciences Inc.

Harvoni contains Ledipasvir; Sofosbuvir.

Harvoni has a total of 33 drug patents out of which 0 drug patents have expired.

Harvoni was authorised for market use on 28 August, 2019.

Harvoni is available in pellets;oral dosage forms.

Harvoni can be used as for the treatment of hepatitis c, for the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; for the treatment of hepatitis c; for treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks.

The generics of Harvoni are possible to be released after 30 July, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US8088368 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8822430 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US9511056 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8841278 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8273341 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8088368

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US9511056

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8822430

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8841278

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8273341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US9393256 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US9393256

(Pediatric)

GILEAD SCIENCES INC Methods for treating HCV
Mar, 2033

(10 years from now)

US10039779

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 28, 2026
New Dosing Schedule (D) Nov 15, 2022

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 28 August, 2019

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks

Dosage: PELLETS;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in